Ad26.ZEBOV, MVA-BN-Filo vaccine — Competitive Intelligence Brief

Ad26.ZEBOV, MVA-BN-Filo vaccine (Ad26.ZEBOV, MVA-BN-Filo vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Viral vector vaccine. Area: Immunology / Infectious Disease.

phase 3 Viral vector vaccine Ebola virus glycoprotein (ZEBOV) Immunology / Infectious Disease Biologic

Target snapshot

Ad26.ZEBOV, MVA-BN-Filo vaccine (Ad26.ZEBOV, MVA-BN-Filo vaccine) — London School of Hygiene and Tropical Medicine. A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ad26.ZEBOV, MVA-BN-Filo vaccine TARGET	Ad26.ZEBOV, MVA-BN-Filo vaccine	London School of Hygiene and Tropical Medicine	phase 3	Viral vector vaccine	Ebola virus glycoprotein (ZEBOV)
rVSV∆G-ZEBOV-GP	rVSV∆G-ZEBOV-GP	University of Birmingham	marketed	Live attenuated viral vector vaccine	Zaire ebolavirus glycoprotein (EBOV-GP)
Intramuscularly administered Ad5-nCoV vaccine	Intramuscularly administered Ad5-nCoV vaccine	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
batch 1 of Ad5-nCoV	batch 1 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
Ad26.COV2.S vaccine	Ad26.COV2.S vaccine	University Medical Center Groningen	marketed	viral vector vaccine	SARS-CoV-2 spike protein
batch 3 of Ad5-nCoV	batch 3 of Ad5-nCoV	Jiangsu Province Centers for Disease Control and Prevention	marketed	viral vector vaccine	SARS-CoV-2 spike protein
TT	TT	CanSino Biologics Inc.	marketed	Viral vector vaccine	SARS-CoV-2 spike protein

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Viral vector vaccine class)

1. Janssen Vaccines & Prevention B.V. · 5 drugs in this class
2. University of Oxford · 3 drugs in this class
3. Crucell Holland BV · 3 drugs in this class
4. National Institute of Allergy and Infectious Diseases (NIAID) · 2 drugs in this class
5. Bharat Biotech International Limited · 2 drugs in this class
6. Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation · 1 drug in this class
7. London School of Hygiene and Tropical Medicine · 1 drug in this class
8. Samia Hassan El-Shishtawy · 1 drug in this class
9. University Medicine Greifswald · 1 drug in this class
10. Aeras · 1 drug in this class